Lexaria Bioscience Corp. LXRP Archives - Page 19 of 27

WednesdayJun 13, 2018 12:06 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Focusing on Delivery of Bioactive Substances via Oral Ingestion

Lexaria has its patented DehydraTECH™ nutrient infusion technology This technology has patent protection for cannabidiol and all other non-psychoactive cannabinoids DehydraTECH™ technology provides greater bio-absorption Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a worldwide leader in enhancing the gastro-intestinal delivery of edible cannabinoid products. The company has its patented nutrient infusion technology called DehydraTECH™. This technology significantly improves the body’s ability to absorb cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, nicotine, drugs, supplements and other beneficial molecules. Lexaria Bioscience is headquartered in Kelowna, British Columbia. Lexaria has patents granted in the United States and Australia for applications of its…

FridayJun 08, 2018 1:32 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Delivers Improved Absorption and Application Versatility

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) DehydraTECH™ enables improved bioabsorption and versatility in drug delivery applications. A recent article discussing the company’s unique technology reads: “DehydraTECH™ is a unique enabling technology from Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) that increases the absorption rate of edible ingestion, delivering five to 10 times more of active ingredients than traditional edibles. This technology is not a competing technology but rather a complementary layer that provides a versatile range of commercial applications. LXRP is the only company in the world that has been awarded a patent for the improved (oral or ingestible)…

TuesdayJun 05, 2018 11:28 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expands Patent Portfolio, Announces Exercise of 450,000 Existing Warrants

LXRP, a drug delivery platform innovator, has been awarded two new patent grants in the U.S. and expects three more from Australia Company already has more than 40 patent awards or applications from 40 countries globally; it is preparing new patent application filings and predicts more patent awards this year LXRP received $63,000 from the exercise of 450,000 warrants previously granted to third parties Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is growing its patent portfolio with two more patent grants in the U.S., predicting three more from Australia, and it is currently preparing new patent application filings as it…

ThursdayMay 31, 2018 9:57 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Outlines Plans to Create Two Wholly Owned Subsidiaries

Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced its intention to create two wholly owned subsidiaries to hold specific intellectual property. The first subsidiary will hold IP related to the improved processing and combustion-free delivery of nicotine and nicotine analogs, while the second subsidiary will hold IP related to the delivery of non-steroidal anti-inflammatory drugs, phosphodiesterase inhibitors and other active pharmaceutical ingredients. Per the update, this proposed structure, which is subject to ongoing legal and tax analysis, more suitably reflects the distinct customer bases and business applications for each subsidiary, allowing the company to…

WednesdayMay 23, 2018 12:07 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Boosts Prospects for Smoke-Free Nicotine Future

New FDA restrictions on Big Tobacco take effect Tobacco manufacturers turning to ‘reduced-risk’ products No edible nicotine products currently available DehydraTECH improves bio-absorption of nicotine taken orally Smoking may be a dying trend, but consumption of nicotine is not only very much alive; its longevity is assured by Big Tobacco’s foray into alternative tobacco and ‘reduced-risk’ products. Driven by increased public awareness and government policy, the pressure has been turned up on smokers to quit, and cigarette manufacturers are feeling the heat, as well. New regulations mandating warnings against the adverse health effects of smoking and the addictive power of…

WednesdayMay 23, 2018 9:50 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Granted Two New US Patents

Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has been granted two new U.S. patents and expects to be granted three additional Australian patents on or before August 17, 2018. Once granted, Lexaria will have four approved patents in the U.S. and four approved patents in Australia. All eight of these patents are within the company’s first patent family, ‘Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof’, and significantly strengthen Lexaria’s intellectual property claims. The company’s growing patent portfolio now includes more than 40 patent applications…

WednesdayMay 16, 2018 12:23 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Strategically Disrupting Drug Delivery

Expanding the applicability of edible delivery technology within the drug industry Creating strategic partnerships through licensing agreements Breakthrough in nicotine absorption study supports further investigation into the many possible uses beyond the cannabis and nicotine industries Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator, partners with leading companies within the drug industry. The company is known primarily for removing objectionable flavors while improving the effectiveness of gastro-intestinal delivery of edible cannabinoid consumer products, but the company is now working to expand the applicability of its technology beyond the cannabis industry. DehydraTECH™ is Lexaria’s edible delivery technology…

MondayMay 14, 2018 3:01 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Awaiting Patent for Promising DehydraTECH Transdermal CBD Application

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) continues to add numerous U.S. and Australian patents to its existing portfolio. Among these is the company’s recent filing for a new transdermal application of cannabidiol (CBD) that followed successful laboratory evaluation of DehydraTECH delivery results. An article discussing the company reads: "LXRP is a British Columbia-based, cannabis-focused food bioscience company, and it is a technology disrupter for edible cannabinoids. Its DehydraTECH technology aids in the body’s absorption of cannabinoids. ... The company’s most recent patent filing follows successful laboratory evaluation of DehydraTECH in the transdermal delivery of cannabidiol (CBD). Results showed an…

MondayMay 14, 2018 1:24 pm

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) Licensing Agreement Renewal with Nuka Enterprises Reinforces DehydraTECH™ Revenue Strategy

Report: LXRP is a ‘compelling investment opportunity’ which is creating recurring licensing revenue that unlocks shareholder value LXRP’s DehydraTECH is a patented delivery technology platform that is renewal-licensed by Nuka in a 10-year semi-exclusive agreement that expands its reach into Canada Company is growing its patent portfolio for proprietary DehydraTECH; it already has patents granted in Australia and the U.S. and has patents pending in more than 40 countries worldwide Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) renewal of its DehydraTECH™ license with Nuka Enterprises LLC could help make it a compelling investment opportunity in the cannabis industry as its…

ThursdayMay 03, 2018 1:21 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters License Agreement with California Cannabis Beverage Maker

Lexaria and GP Holdings LLC enter into a five-year semi-exclusive licensing agreement Lexaria and GP have developed a series of high-performing cannabis beverages with nearly zero unwanted taste and odor California cannabis-beverage market is expected to be one of the largest edible product segments Drug delivery innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) recently announced a definitive technology licensing agreement with GP Holdings LLC to empower next-generation performance in high absorption, fast acting cannabis-infused beverages to be developed and sold in California. DehydraTECH™ is LXRP’s edible delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP